Home › Funds › Foresite Capital Management VI LLC › AVBP
Foresite Capital Management VI LLC position in AVBP
ARRIVENT BIOPHARMA INC · Health Care
Foresite Capital Management VI LLC reported holding 490,341 shares of AVBP (ARRIVENT BIOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$14.8M, representing 2.62% of its reported portfolio and ranking #13 among its reported holdings. Foresite Capital Management VI LLC has disclosed AVBP holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Foresite Capital Management VI LLC's AVBP position evolved
Foresite Capital Management VI LLC first disclosed a stake in AVBP in Q2 2026 at 301,341 shares (US$10.5M). The position peaked in Q3 2026 at 490,341 shares, worth US$14.8M. Across 2 filings, Foresite Capital Management VI LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 490,341 shares valued at US$14.8M — an increase of 189,000 shares quarter over quarter.. Notable position changes include a 63% increase in Q3 2026 (shares fell 62% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 301.34K | $10.47M | New |
| Q3 2026 | 490.34K | $14.85M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AVBP and 13F data
AVBP (ARRIVENT BIOPHARMA INC) is a Health Care company. 51 other funds we track also report a position in AVBP — the largest reported positions include MONTANOVA CAPITAL, LLC (US$149.1M), INFINITUM ASSET MANAGEMENT, LLC (US$137.0M), Hillhouse Capital (HHLR Advisors) (US$119.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVBP
- MONTANOVA CAPITAL, LLC 4.93M sh · $149.15M · Q3 2026
- INFINITUM ASSET MANAGEMENT, LLC 4.52M sh · $136.98M · Q3 2026
- Hillhouse Capital (HHLR Advisors) 3.93M sh · $118.97M · Q3 2026
- ORBIMED ADVISORS LLC 3.03M sh · $91.67M · Q3 2026
- Octagon Capital Advisors LP 2.14M sh · $64.84M · Q3 2026
- Vivo Capital, LLC 1.79M sh · $54.11M · Q3 2026
- Sofinnova Investments, Inc. 1.70M sh · $51.38M · Q3 2026
- General Catalyst Group Management, LLC 1.49M sh · $45.26M · Q3 2026
- Logos Global Management LP 1.35M sh · $40.88M · Q3 2026
- Novo Holdings A/S 1.18M sh · $35.58M · Q3 2026
- HSG Holding Ltd 663.31K sh · $20.08M · Q3 2026
- Seven Fleet Capital Management LP 451.17K sh · $13.66M · Q3 2026
More on Foresite Capital Management VI LLC
FAQ
How long has Foresite Capital Management VI LLC held AVBP?
Foresite Capital Management VI LLC has disclosed AVBP holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Foresite Capital Management VI LLC's current position in AVBP?
As of Q3 2026, Foresite Capital Management VI LLC holds 490.34K shares of AVBP (ARRIVENT BIOPHARMA INC), valued at $14.85M, representing 2.62% of its reported portfolio and ranking #13.
Has Foresite Capital Management VI LLC been buying or selling AVBP?
In the latest 13F filing (Q3 2026), Foresite Capital Management VI LLC increased its position in AVBP. The position peaked in Q3 2026 at 490.34K shares.
Which other funds hold AVBP?
Other major institutional holders of AVBP include MONTANOVA CAPITAL, LLC, INFINITUM ASSET MANAGEMENT, LLC, Hillhouse Capital (HHLR Advisors), among 51 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.